News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

StemCells Inc. (STEM) To Discuss Plans For Advancing Clinical Studies In Spinal Cord Injury And Age Related Macular Regeneration


1/7/2014 9:17:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Calif., Jan. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Eliseo Salinas, M.D., Executive Vice President and Head of Research and Development, will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary HuCNS-SCĀ® human neural stem cells, at the 2014 Alliance for Regenerative Medicine (ARM) State of the Industry Briefing. Dr. Salinas will discuss the Company's plans for completing ongoing safety studies in spinal cord injury and age related macular degeneration (AMD) in the first and second quarters of 2014 respectively, as well as the planned initiation of controlled Phase II efficacy studies in both indications in 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES